Medical Condition News

RSS

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

COX-2 expression not an adequate independent prognostic factor: Research

Cyclooxygenase-2 represents a key modulatory molecule in inflammation and carcinogenesis. COX-2 is known to have multiple tumorigenic effects. Increased expression of COX-2 has been observed in a variety of tumors including pancreatic cancer.

22 Apr 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

Age delays time taken for recovery of sense of taste following nerve injury

Age dramatically delays the time if takes to recover the sense of taste following a significant nerve injury, Medical College of Georgia researchers said.

22 Apr 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

Secrets, solutions, strategies and shortcuts to win against personal autism challenges

Howard Rodgers remembers the day his son was born. His mind was teeming with positive thoughts about how this small child would change the world. Then, reality came back - for a very long visit. His son was diagnosed with one of the worst cases of autism doctors and specialists had ever seen.

22 Apr 2010

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Kathleen Keef, Ph.D., professor of physiology and cell biology at the University of Nevada School of Medicine, has been awarded a four-year, $1.2 million grant from the National Institute of Health to study the control of motility in the internal anal sphincter.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

22 Apr 2010

Non-invasive coronary CTA cost-effective alternative to invasive cardiac catheterization for CAD evaluation

According to a study conducted at Thomas Jefferson University (TJU), non-invasive coronary computed tomography angiography (CTA) is a cost-effective alternative to invasive cardiac catheterization in the care of patients who have positive stress test results but a less than 50 percent chance of actually having significant coronary artery disease (CAD). The study will be published in the May issue of the American Journal of Roentgenology.

22 Apr 2010

Penn State researchers to test education program on patients with high blood pressure

When it comes to chronic diseases, knowledge is power, according to Penn State researchers who will test an education program on patients with high blood pressure to help them manage their disease.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Framingham risk assessment tool fails to predict patients with suspected CAD: Study

If patients with suspected coronary artery disease are excluded from further screening because of a low Framingham score, many patients with substantial atherosclerosis (a build-up of plaque inside the arteries) will be missed, according to a study published in the May issue of the American Journal of Roentgenology.

22 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

SpectraCell Laboratories introduces apolipoprotein E genotyping

Effective immediately, SpectraCell Laboratories now offers apolipoprotein E genotyping. This test determines a person's genetic risk for heart disease associated with the commonly studied gene called apoE, which is involved in the metabolism of cholesterol and triglycerides (fats in the blood).

22 Apr 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

22 Apr 2010

NO-naproxen blocks molecular changes leading to colorectal cancer development

Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

22 Apr 2010

Aspen Dental donates $2,300 to Oral Cancer Foundation for cancer detection and treatment

Aspen Dental announced today that the company will donate $2,300 to the Oral Cancer Foundation as part of its commitment to oral cancer detection and treatment. The amount represents a $5 donation for every Vizilite Plus screening conducted at Aspen Dental offices during Oral, Head, and Neck Cancer Awareness Week (April 12-18, 2010).

22 Apr 2010

Medical Condition News

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

COX-2 expression not an adequate independent prognostic factor: Research

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Age delays time taken for recovery of sense of taste following nerve injury

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

Research findings may help personalize use of statins, scientists say

Secrets, solutions, strategies and shortcuts to win against personal autism challenges

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Non-invasive coronary CTA cost-effective alternative to invasive cardiac catheterization for CAD evaluation

Penn State researchers to test education program on patients with high blood pressure

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Framingham risk assessment tool fails to predict patients with suspected CAD: Study

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

SpectraCell Laboratories introduces apolipoprotein E genotyping

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

NO-naproxen blocks molecular changes leading to colorectal cancer development

Aspen Dental donates $2,300 to Oral Cancer Foundation for cancer detection and treatment

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News